Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years. On February 6, Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia to $4 from $6 and kept an Overweight rating. This adjustment was made as part of a broader review of commercial-stage companies, with the firm updating estimates and price targets following several year-end preliminary reports and ahead of official Q4 2025 results.
In Q3, Akebia Therapeutics Inc. (NASDAQ:AKBA) reported total revenue of $58.8 million with a net income of $540,000, successfully pivoting from a $20 million net loss in Q3 2024. While the launch of its dialysis drug Vafseo saw lower-than-expected revenue of $14.3 million due to operational and adherence hurdles, the company expanded its patient access to 70,000 and reached a milestone of over 700 active prescribers.
Despite an anticipated temporary revenue dip in Q4 due to inventory adjustments at US Renal Care, management projects growth to resume in Q1 2026. The company remains focused on its 2026 pipeline outlook, including the initiation of a Phase 2 rare kidney disease study, while maintaining that its current cash reserves are sufficient to fund its path toward sustained profitability.
Photo by RephiLe water on Unsplash
Akebia Therapeutics Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes therapeutics for patients with kidney diseases.
While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
